Mach One has entered into a multi-year, sole-source agreement with PanTheryx, to supply proprietary bio-based ingredients for manufacturing a broad-spectrum pediatric diarrhea product. Through a wholly owned subsidiary
Takeda Canada has re-acquired the Canadian commercial rights to ACTOS, an oral treatment for type 2 diabetes, from Eli Lilly Canada. Takeda, the discoverer of ACTOS, licensed the
AspenBio has received a request from the FDA for additional information related to its Premarket Notification 510(k) application for AppyScore test. The application was filed in late June
Ortho-McNeil-Janssen has reported that the FDA has issued a complete response letter regarding its New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development. The NDA was
Our government is committed to building a competitive advantage for the Canadian private sector and supports these leading-edge technology solutions, said Greg Rickford, Member of Parliament for Kenora.
LifeCycle Pharma has reported a net loss of DKK 144.3m for the first half of 2009, compared to a net loss of DKK140.3m for the same period in
ZymoGenetics has reported the submission of a Citizen Petition to the FDA, requesting the removal of Thrombin-JMI Thrombin, topical (bovine origin) from the market, in the interest of
The Maryland Department of Health has selected Upp Technology to help improve the efficiency of their emergency operations. Upp, a provider of public health solutions, will provide a
Bristol-Myers Squibb has reported that the US District Court for the Southern District of New York has granted preliminary approval of settlement of Sampson v. Robinson, et al.,
INVISTA has signed a technology licensing agreement with Chongqing Jian-Feng Industrial Group, to license its BDO and PTMEG manufacturing technologies to the Chinese company. Jian-Feng is investing RMB2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.